• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

    11/1/23 8:07:21 AM ET
    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Specialty Stores
    Consumer Discretionary
    Get the next $BCLI alert in real time by email

    Gainers

    Cellectis S.A. (NASDAQ:CLLS) shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.

    GDEV Inc. (NASDAQ:GDEV) shares rose 26.2% to $2.55 in pre-market trading after falling 11% on Tuesday.

    Sientra, Inc. (NASDAQ:SIEN) shares rose 24.7% to $0.7980 in pre-market trading. Sientra shares fell 56% on Tuesday after the company withdrew its FY23 guidance and reported interim third-quarter financial results.

    Bruush Oral Care Inc. (NASDAQ:BRSH) rose 16.6% to $0.2751 in pre-market trading after falling 17% on Tuesday.

    Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ:BHAT) shares climbed 15% to $0.9999 in pre-market trading after falling 10% on Tuesday.

    NOVONIX Limited (NASDAQ:NVX) shares gained 14.8% to $2.10 in pre-market trading. NOVONIX said its NOVONIX Anode Materials division finalized its $100 million grant award from the U.S. Department of Energy.

    Society Pass Incorporated (NASDAQ:SOPA) shares jumped 14.1% to $0.4297 in pre-market trading.

    DBV Technologies S.A. (NASDAQ:DBVT) rose 11.8% to $1.13 in pre-market trading after the company announced the receipt of written feedback from the U.S. FDA regarding the remaining study design elements for the COMFORT supplemental safety studies. The company also reported results for the third quarter.

    Plus Therapeutics, Inc. (NASDAQ:PSTV) shares rose 11.3% to $1.37 in pre-market trading after the company reported third-quarter financial results and announced a share repurchase program.

    FLJ Group Limited (NASDAQ:FLJ) gained 9.3% to $0.2733 in pre-market trading. FLJ Group reported disposal of long-term apartment rental business.

    Losers

    WeWork Inc. (NYSE:WE) dipped 37.3% to $1.43 in pre-market trading. According to a Wall Street Journal report citing people familiar with the matter, WeWork plans to file for Chapter 11 bankruptcy in New Jersey as soon as next week.

    Paycom Software, Inc. (NYSE:PAYC) shares fell 37.1% to $154.15 in pre-market trading after the company reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates. Several analysts also downgraded the stock today.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares fell 30.5% to $0.41 in pre-market trading after the company reported topline results from Phase 2 proof-of-concept study of TNX-601 ER for the treatment of major depressive disorder.

    Big 5 Sporting Goods Corporation (NASDAQ:BGFV) shares fell 16.6% to $5.89 in pre-market trading after the company reported weaker-than-expected results for its third quarter.

    Tempo Automation Holdings, Inc. (NASDAQ:TMPO) shares fell 13.6% to $0.0717 in pre-market trading after dipping 30% on Tuesday.

    Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 13.3% to $0.1326 in pre-market trading.

    Yum China Holdings, Inc. (NYSE:YUMC) shares fell 12.4% to $46.00 in pre-market trading after the company reported worse-than-expected financial results for its third quarter.

    BAIYU Holdings, Inc. (NASDAQ:BYU) fell 12% to $1.83 in pre-market after dipping 19% on Tuesday.

    Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) fell 11.2% to $1.10 in pre-market trading. Lexicon Pharmaceuticals said Matthew Cullen is joining the company as vice president of value and access, effective Nov. 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective Nov. 13, 2023.

    Recon Technology, Ltd. (NASDAQ:RCON) shares fell 9.9% to $0.2081 in pre-market trading. The company recently said total revenue fell 19.9% to RMB67.1 million ($9.3 million) for the year ended June 30, 2023.

    Now Read This: QUALCOMM Likely To Report Lower Q4 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $BGFV
    $BHAT
    $BRSH

    CompanyDatePrice TargetRatingAnalyst
    Cellectis S.A.
    $CLLS
    2/17/2026$7.00Buy
    Jefferies
    Paycom Software Inc.
    $PAYC
    2/12/2026$175.00 → $137.00Market Perform
    BMO Capital Markets
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Paycom Software Inc.
    $PAYC
    12/17/2025$195.00Buy
    BTIG Research
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Paycom Software Inc.
    $PAYC
    9/26/2025$270.00Buy
    Guggenheim
    Paycom Software Inc.
    $PAYC
    9/22/2025$258.00Hold → Buy
    TD Cowen
    More analyst ratings

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paycom Releases Automated Career and Succession Planning Tool

    Paycom Software, Inc. (NYSE:PAYC) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, today announced the launch of Career and Succession Planning, an automated tool to easily identify successors for companywide roles, assess bench strength and ensure talent management and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310212643/en/Paycom announces the launch of its Career and Succession Planning tool. Without forward-thinking talent management, organizations risk disruption and uncertainty when leadership gaps arise. Career and Succession Planning seamlessly syncs with

    3/10/26 4:05:00 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

    Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary endpoints as compared to placebo In pooled post hoc analysis of the pivotal RELIEF and RELISIENT studies, TONMYA showed favorable benefit-risk profile using number needed to treat, number needed to harm, and likelihood to be helped or harmed BERKELEY HEIGHTS, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, com

    3/10/26 8:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/23/26 7:49:43 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Human Resources Mcdermott Wendy converted options into 224,406 shares and covered exercise/tax liability with 68,107 shares, increasing direct ownership by 128% to 277,945 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:59 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Partnerships & Corp Strat Martens Rachel Yap converted options into 67,090 shares and covered exercise/tax liability with 35,826 shares (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:20 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Medical Officer Granowitz Craig B converted options into 312,276 shares and covered exercise/tax liability with 109,098 shares, increasing direct ownership by 169% to 323,430 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:19:33 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Cellectis with a new price target

    Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00

    2/17/26 7:48:16 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Paycom Software with a new price target

    BMO Capital Markets reiterated coverage of Paycom Software with a rating of Market Perform and set a new price target of $137.00 from $175.00 previously

    2/12/26 6:46:23 AM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    SEC Filings

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/10/26 8:05:34 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NOVONIX Limited

    6-K - NOVONIX Ltd (0001859795) (Filer)

    3/9/26 5:30:13 PM ET
    $NVX
    Industrial Machinery/Components
    Miscellaneous

    SEC Form RW filed by PLUS THERAPEUTICS Inc.

    RW - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/6/26 4:05:32 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

    Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. "Following U.S. Food a

    11/10/25 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Paycom Software Inc.

    SC 13D/A - Paycom Software, Inc. (0001590955) (Subject)

    12/13/24 7:06:11 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $BGFV
    $BHAT
    $BRSH
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

    THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w

    2/26/26 8:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care